Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Radiol ; 92(1104): 20190473, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31386554

ABSTRACT

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis which can have a broad range of clinical and radiological presentations. Typically, ECD affects multiple organ systems, with skeletal involvement present in almost all ECD patients and cardiothoracic manifestations in more than half. Cardiac and thoracic involvement contributes significantly to morbidity and mortality in affected patients and may have prognostic implications. The diagnosis of ECD can be challenging due to its rarity and similarity to other systemic disease processes. Although the diagnosis can be suggested on imaging, histopathology and immunohistochemistry are required for confirmation. We describe the multimodal imaging features of mediastinal, cardiac, pleural and lung parenchymal ECD. This review identifies the most common radiological manifestations of cardiac and thoracic ECD on contrast-enhanced CT, fluorine18-fludeoxyglucose positron emission tomography/CT and cardiac MRI, and highlights the role of these cross-sectional techniques in disease diagnosis.


Subject(s)
Erdheim-Chester Disease/diagnostic imaging , Heart Diseases/diagnostic imaging , Lung Diseases/diagnostic imaging , Mediastinal Diseases/diagnostic imaging , Multimodal Imaging/methods , Contrast Media , Erdheim-Chester Disease/complications , Fluorodeoxyglucose F18 , Heart Diseases/etiology , Humans , Lung Diseases/etiology , Magnetic Resonance Imaging , Mediastinal Diseases/etiology , Pleural Diseases/diagnostic imaging , Pleural Diseases/etiology , Positron Emission Tomography Computed Tomography/methods , Radiopharmaceuticals , Tomography, X-Ray Computed/methods
2.
J Nucl Med ; 57 Suppl 1: 53S-9S, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26834103

ABSTRACT

The success of breast cancer therapy is ultimately defined by clinical endpoints such as survival. It is valuable to have biomarkers that can predict the most efficacious therapies or measure response to therapy early in the course of treatment. Molecular imaging has a promising role in complementing and overcoming some of the limitations of traditional biomarkers by providing the ability to perform noninvasive, repeatable whole-body assessments. The potential advantages of imaging biomarkers are obvious and initial clinical studies have been promising, but proof of clinical utility still requires prospective multicenter clinical trials.


Subject(s)
Biomarkers, Tumor , Breast Neoplasms/diagnostic imaging , Molecular Imaging/methods , Female , Humans , Positron-Emission Tomography/methods , Tomography, Emission-Computed, Single-Photon/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...